Prestige Consumer Healthcare (PBH) Cash & Equivalents (2010 - 2025)

Prestige Consumer Healthcare's Cash & Equivalents history runs 16 years deep, the most recent figure standing at $62.4 million for Q4 2025.

• In Q4 2025, Cash & Equivalents rose 22.6% year-over-year to $62.4 million; the TTM figure through Dec 2025 stood at $62.4 million (up 22.6% YoY), while the FY2025 annual figure was $97.9 million, up 110.64% from the prior year.
• Cash & Equivalents was $62.4 million for Q4 2025 at Prestige Consumer Healthcare, down from $119.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $163.6 million in Q2 2021 to a low of $21.0 million in Q4 2021.
• Historically, Cash & Equivalents has averaged $64.5 million across 5 years, with a median of $53.1 million in 2023.
• Biggest YoY gain for Cash & Equivalents was 310.88% in 2022; the steepest drop was 78.08% in 2022.
• A 5-year view of Cash & Equivalents shows it stood at $21.0 million in 2021, then surged by 310.88% to $86.4 million in 2022, then declined by 26.34% to $63.6 million in 2023, then fell by 20.03% to $50.9 million in 2024, then advanced by 22.6% to $62.4 million in 2025.
• The last three Cash & Equivalents figures came in at $62.4 million (Q4 2025), $119.1 million (Q3 2025), and $139.5 million (Q2 2025), per Business Quant data.